City

Beijing (1)

Condition

Targeted Molecular Therapy (3)

Biliary Tract Cancer (1)

Capecitabine (1)

Effectiveness (1)

Feasibility (1)

Programmed Cell Death 1 Ligand 1 Gene Mutation (1)

Renal Neoplasms (1)

Safety (1)

Overall Status

Not yet recruiting (3)

Sign in for free

Phase

n/a (1)

phase 2 (1)

Sponsor

Beijing Friendship Hospital (1)

First Affiliated Hospital, Sun Yat-Sen University (1)

The University of Hong Kong-Shenzhen Hospital (1)

Collaborator

Health Science Center of Xi'an Jiaotong University (1)

Sun Yat-sen University (1)

Tianjin Happy Life Technology Co., Ltd. (1)

Yantai Yuhuangding Hospital (1)

Intervention

apatinib (1)

camrelizumab (1)

capecitabine (1)

sunitinib (1)

targeted therapy (1)

Study Documents

Intervention Type

drug (3)

Funder Type

Other (3)

Study Type

Interventional (2)

Observational (1)

targeted molecular therapy

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Patients With Advanced Refractory Solid Tumors

Not yet recruiting

Feasibility
+3 more

Targeted therapy

(no location specified)

Dec 14, 2021

Biliary Tract Cancer, Programmed Cell Death 1 Ligand 1 Gene Mutation, Targeted Molecular Therapy Trial in Beijing (Camrelizumab,

Not yet recruiting

Biliary Tract Cancer
+3 more

Camrelizumab
+2 more

Beijing, Beijing, China

Beijing Friendship Hospital

Jan 20, 2021

Renal Tumors, Targeted Molecular Therapy Trial (sunitinib)

Not yet recruiting

Renal Neoplasms
Targeted Molecular Therapy

sunitinib

(no location specified)

Feb 24, 2016